Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science reported Q1FY26 revenue of ₹11,197m, up 6.2% year-on-year. Gross margin expanded 300bps to 60.3%, driving EBITDA up 14.8% YoY to ₹2,181m with margin at 19.5% (up 150bps). Operational PAT jumped 80.6% YoY to ₹1,140m, with operational EPS at ₹12.4 versus ₹6.9 last year. US business revenue grew 7% YoY to $71m, while the company maintained a US business outlook of ~$400m by FY27-28. Net debt reduced by ₹264m to ₹14,958m, ROCE stood at 15.1%, and credit rating was upgraded to 'CARE A Positive'. Note: Q1FY25 figures were restated following the demerger of the Softgel business.
Strong quarterly performance with healthy margin expansion, record PAT, and improving balance sheet metrics is a positive signal for shareholders. Credit rating upgrade and debt reduction suggest improving financial health, though sequential revenue dipped 5.9% QoQ and Access Markets remain weak due to donor funding issues.